购物车
全部删除
您的购物车当前为空
Etofylline clofibrate has a hypolipidemic and antithrombotic effect and it also has an agonistic interaction with intimal PGI2.

Etofylline clofibrate has a hypolipidemic and antithrombotic effect and it also has an agonistic interaction with intimal PGI2.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 374 | 5日内发货 | |
| 5 mg | ¥ 622 | 5日内发货 | |
| 10 mg | ¥ 997 | 5日内发货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,090 | 5日内发货 |
| 产品描述 | Etofylline clofibrate has a hypolipidemic and antithrombotic effect and it also has an agonistic interaction with intimal PGI2. |
| 体内活性 | Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time). It has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively. |
| 分子量 | 420.85 |
| 分子式 | C19H21ClN4O5 |
| CAS No. | 54504-70-0 |
| 密度 | 1.37g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 52 mg/mL (123.56 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (5.94 mM), Sonication is recommeded. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多